QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
Positive News SentimentPositive News
NASDAQ:ELEV

Elevation Oncology (ELEV) Stock Forecast, Price & News

$0.69
+0.04 (+6.15%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.65
▼
$0.73
50-Day Range
$0.65
▼
$1.56
52-Week Range
$0.64
▼
$5.89
Volume
92,772 shs
Average Volume
924,563 shs
Market Capitalization
$29.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Elevation Oncology MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
576.4% Upside
$4.67 Price Target
Short Interest
Healthy
5.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.56) to ($1.22) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

543rd out of 964 stocks

Biological Products, Except Diagnostic Industry

85th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

ELEV stock logo

About Elevation Oncology (NASDAQ:ELEV) Stock

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

ELEV Price History

ELEV Stock News Headlines

September 5, 2023 | finance.yahoo.com
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 23, 2023 | bizjournals.com
Fore Biotherapeutics raises $75M to advance potential cancer therapy, announces CEO departure
September 26, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 17, 2023 | msn.com
Elevation Oncology doses first patient in solid tumours therapy trial
August 16, 2023 | finance.yahoo.com
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
July 15, 2023 | finance.yahoo.com
ELEV - Elevation Oncology, Inc.
July 13, 2023 | seekingalpha.com
Elevation Oncology gets new CEO and promotes to CFO
July 13, 2023 | marketwatch.com
Elevation Oncology Names Ferra CEO, Furlong Finance Chief >ELEV
September 26, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
July 13, 2023 | finance.yahoo.com
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer
June 9, 2023 | benzinga.com
Elevation Oncology shares are trading lower after the company announced a $50 million public offering.
June 9, 2023 | marketwatch.com
Elevation Oncology Shares Tumble Premarket After Stock Offering >ELEV
June 9, 2023 | msn.com
Elevation Oncology Plummets on $50M Public Offering
June 9, 2023 | investorplace.com
Why Is Elevation Oncology (ELEV) Stock Down 26% Today?
June 9, 2023 | seekingalpha.com
Elevation Oncology slumps 25%, prices $50M public offering
June 9, 2023 | msn.com
Elevation Oncology slumps 25% on $50M public offering pricing
June 9, 2023 | finance.yahoo.com
Elevation Oncology Announces Pricing of $50 Million Public Offering
June 8, 2023 | marketwatch.com
Elevation Oncology Shares Fall After Proposed Public Offering
June 8, 2023 | finance.yahoo.com
Elevation Oncology Announces Launch of Proposed Public Offering
June 6, 2023 | msn.com
Wedbush Maintains Elevation Oncology (ELEV) Outperform Recommendation
June 3, 2023 | finance.yahoo.com
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
May 26, 2023 | seekingalpha.com
Elevation Oncology up 61% on early-stage data for gastric cancer treatment
May 26, 2023 | msn.com
Elevation Oncology Blasts Higher on New Cancer Treatment
May 26, 2023 | fool.com
Elevation Oncology (NASDAQ: ELEV)
May 26, 2023 | investorplace.com
Why Is Elevation Oncology (ELEV) Stock Up 57% Today?
May 19, 2023 | finance.yahoo.com
Private equity firms among Elevation Oncology, Inc.'s (NASDAQ:ELEV) largest shareholders, saw gain in holdings value after stock jumped 34% last week
May 15, 2023 | finance.yahoo.com
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements
See More Headlines
Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

ELEV Company Calendar

Last Earnings
8/03/2023
Today
9/26/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELEV
CUSIP
N/A
CIK
1783032
Web
www.elevationoncology.com
Phone
716-371-1125
Fax
N/A
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+576.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($6.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-95,080,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-280.92%
Return on Assets
-158.79%

Debt

Debt-to-Equity Ratio
0.41
Current Ratio
13.00
Quick Ratio
13.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.10 per share
Price / Book
0.33

Miscellaneous

Outstanding Shares
42,380,000
Free Float
36,067,000
Market Cap
$29.24 million
Optionable
Not Optionable
Beta
0.33
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. David Dornan Ph.D. (Age 45)
    Chief Scientific Officer
    Comp: $545.5k
  • Dr. Shawn M. Leland Pharm.D. (Age 39)
    R.Ph., Advisor
    Comp: $881.58k
  • Ms. Valerie Malyvanh Jansen M.D. (Age 45)
    Ph.D., Chief Medical Officer
    Comp: $641.53k
  • Mr. Joseph J. Ferra Jr. (Age 48)
    CEO, Pres & Director
  • Ms. Tammy Furlong CPA
    P.M.P., CFO & Sec.
  • Mr. Ryan Bloomer
    Head of Tech Ops
  • Candice Masse
    Sr. Director of Corp. Communications & Investor Relations
  • Mr. Robert C. Yang
    VP of Legal Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ELEV Stock - Frequently Asked Questions

Should I buy or sell Elevation Oncology stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ELEV shares.
View ELEV analyst ratings or view top-rated stocks.

What is Elevation Oncology's stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month price targets for Elevation Oncology's shares. Their ELEV share price forecasts range from $2.00 to $8.00. On average, they anticipate the company's stock price to reach $4.67 in the next year. This suggests a possible upside of 576.4% from the stock's current price.
View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts.

How have ELEV shares performed in 2023?

Elevation Oncology's stock was trading at $0.95 at the start of the year. Since then, ELEV stock has decreased by 27.4% and is now trading at $0.6899.
View the best growth stocks for 2023 here.

When is Elevation Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ELEV earnings forecast.

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.09.

When did Elevation Oncology IPO?

(ELEV) raised $1 billion in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

What is Elevation Oncology's stock symbol?

Elevation Oncology trades on the NASDAQ under the ticker symbol "ELEV."

Who are Elevation Oncology's major shareholders?

Elevation Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include venBio Partners LLC (6.88%), ExodusPoint Capital Management LP (6.16%), Sphera Funds Management LTD. (2.12%), Citadel Advisors LLC (1.98%), Hudson Bay Capital Management LP (1.29%) and Velan Capital Investment Management LP (1.17%). Insiders that own company stock include Global Hc Fund Pte Vertex II, Global Strategic Fund I Venbio and Yun-Lung Chen.
View institutional ownership trends.

How do I buy shares of Elevation Oncology?

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Elevation Oncology's stock price today?

One share of ELEV stock can currently be purchased for approximately $0.69.

How much money does Elevation Oncology make?

Elevation Oncology (NASDAQ:ELEV) has a market capitalization of $29.24 million. The company earns $-95,080,000.00 in net income (profit) each year or ($6.85) on an earnings per share basis.

How can I contact Elevation Oncology?

The official website for the company is www.elevationoncology.com. The company can be reached via phone at 716-371-1125 or via email at ir@elevationoncology.com.

This page (NASDAQ:ELEV) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -